Instil Bio (TIL) FCF Margin (2020)
Instil Bio (TIL) posted quarterly FCF Margin of 15142.31% for Q3 2020, down 40.98% quarter-over-quarter from 10740.48% in Q2 2020.
Instil Bio (TIL) FCF Margin (2020) Analysis & Trends
Instil Bio's FCF Margin history runs 1 years deep, the most recent figure standing at 15142.31% for Q3 2020.
- In Q3 2020, FCF Margin changed N/A year-over-year to 15142.31%; the TTM figure through Jun 2021 stood at 271550.0% (changed N/A YoY), while the FY2020 annual figure was 58284.06%, changed N/A from the prior year.
- FCF Margin for Q3 2020 stood at 15142.31%, down from 10740.48% in the prior quarter.
- The five-year high for FCF Margin was 5204.55% in Q1 2020, with the low at 15142.31% in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -15,142.31% |
| Jun 30, 2020 | -10,740.48% |
| Mar 31, 2020 | -5,204.55% |